Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kamel Laribi

Showing results (101-110 of 107) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 107 results.
American Journal of Hematology|July 8, 2025
Durable Responses With Front-Line Rituximab in Autoimmune Cytopenias Associated With Indolent B-Cell ClonesYoann Zadro, Amélie Lusque, Héloïse Rey, et al.
Blood Advances|April 14, 2026
Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA studyVincent Camus, Daphné Krzisch, Alessio Bruscaggin, et al.
Haematologica|April 20, 2023
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 studyAlexis Talbot, Arthur Bobin, Léa Tabone, et al.
Clinical and Experimental Rheumatology|May 17, 2022
Venous thromboembolism during systemic inflammatory and autoimmune diseases associated with myelodysplastic syndromes, chronic myelomonocytic leukaemia and myelodysplastic/myeloproliferative neoplasms: a French multicentre retrospective case-control studyMarie Péan de Ponfilly-Sotier, Vincent Jachiet, Ygal Benhamou, et al.
Neurology|January 8, 2020
Management and outcome of primary CNS lymphoma in the modern era: An LOC network studyCaroline Houillier, Carole Soussain, Hervé Ghesquières, et al.
Nature Medicine|June 3, 2024
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trialXavier Leleu, Cyrille Hulin, Jerome Lambert, et al.
Eclinicalmedicine|November 30, 2023
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONYThomas Chatzikonstantinou, Lydia Scarfò, Georgios Karakatsoulis, et al.
Pageof 11

Showing results (101-110 of 107) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 107 results.
American Journal of Hematology|July 8, 2025
Durable Responses With Front-Line Rituximab in Autoimmune Cytopenias Associated With Indolent B-Cell ClonesYoann Zadro, Amélie Lusque, Héloïse Rey, et al.
Blood Advances|April 14, 2026
Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA studyVincent Camus, Daphné Krzisch, Alessio Bruscaggin, et al.
Haematologica|April 20, 2023
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 studyAlexis Talbot, Arthur Bobin, Léa Tabone, et al.
Clinical and Experimental Rheumatology|May 17, 2022
Venous thromboembolism during systemic inflammatory and autoimmune diseases associated with myelodysplastic syndromes, chronic myelomonocytic leukaemia and myelodysplastic/myeloproliferative neoplasms: a French multicentre retrospective case-control studyMarie Péan de Ponfilly-Sotier, Vincent Jachiet, Ygal Benhamou, et al.
Neurology|January 8, 2020
Management and outcome of primary CNS lymphoma in the modern era: An LOC network studyCaroline Houillier, Carole Soussain, Hervé Ghesquières, et al.
Nature Medicine|June 3, 2024
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trialXavier Leleu, Cyrille Hulin, Jerome Lambert, et al.
Eclinicalmedicine|November 30, 2023
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONYThomas Chatzikonstantinou, Lydia Scarfò, Georgios Karakatsoulis, et al.
Pageof 11